These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 30678445)
21. Current strategies for the treatment of ulcerative colitis. Yadav PK; Liu Z Recent Pat Inflamm Allergy Drug Discov; 2009 Jan; 3(1):65-72. PubMed ID: 19149748 [TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250 [TBL] [Abstract][Full Text] [Related]
31. Golimumab in unresponsive ulcerative colitis. Lippert E; Müller M; Ott C Biologics; 2014; 8():207-10. PubMed ID: 24904202 [TBL] [Abstract][Full Text] [Related]
32. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES. Teixeira FV; Damião AOMC; Kotze PG Arq Gastroenterol; 2018; 55(2):198-200. PubMed ID: 30043874 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis. Pellet G; Stefanescu C; Carbonnel F; Peyrin-Biroulet L; Roblin X; Allimant C; Nachury M; Nancey S; Filippi J; Altwegg R; Brixi H; Fotsing G; de Rosamel L; Shili S; Laharie D; Clin Gastroenterol Hepatol; 2019 Feb; 17(3):494-501. PubMed ID: 30213584 [TBL] [Abstract][Full Text] [Related]
34. [New advances in the treatment of inflammatory bowel disease]. Chaparro M Gastroenterol Hepatol; 2013 Oct; 36 Suppl 2():21-9. PubMed ID: 24160949 [TBL] [Abstract][Full Text] [Related]
35. Ischemic colitis induced by indigo naturalis in a patient with ulcerative colitis: a case report. Cho B; Yoon SM; Son SM; Kim HW; Kim KB; Youn SJ BMC Gastroenterol; 2020 May; 20(1):154. PubMed ID: 32414334 [TBL] [Abstract][Full Text] [Related]
36. A review of infliximab use in ulcerative colitis. Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261 [TBL] [Abstract][Full Text] [Related]
37. An update on anti-TNF agents in ulcerative colitis. Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254 [TBL] [Abstract][Full Text] [Related]
38. Golimumab for the treatment of ulcerative colitis. Flamant M; Paul S; Roblin X Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597 [TBL] [Abstract][Full Text] [Related]
39. The safety of biological pharmacotherapy for the treatment of ulcerative colitis. Fiorino G; Bonovas S; Cicerone C; Allocca M; Furfaro F; Correale C; Danese S Expert Opin Drug Saf; 2017 Apr; 16(4):437-443. PubMed ID: 28279079 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]